Global biotechnology leader Amgen has finalized a structured executive succession plan following the announced retirement of its Chief Financial Officer (CFO), Peter Griffith. The multinational drugmaker has selected Thomas Dittrich to assume the corporate finance portfolio, with the formal appointment taking effect in September. To preserve operational continuity across the enterprise, Griffith, who managed Amgen’s financial operations since 2020 and anchored its long-term growth initiatives, will maintain an advisory presence at the organization through January 2027 to facilitate the leadership handover.
The integration pipeline for the incoming executive outlines distinct transitional phases:
-
July 1 to August 31: Dittrich will return to the corporate structure, functioning initially as Executive Vice President.
-
September 1: He will officially step into the CFO mandate, reporting directly to Amgen’s Chief Executive Officer (CEO), Robert Bradway.
Dittrich possesses extensive institutional familiarity with Amgen’s operational ecosystem, having previously spent approximately eight years within the company executing various senior accounting and financial responsibilities, including tenures as Chief Accounting Officer and Head of Corporate Planning. Prior to navigating this return to the biopharmaceutical manufacturer, his executive career featured a recent tenure as the CFO of Swiss-based medical dermatology specialist Galderma Group. Additionally, his background includes global financial leadership mandates at corporate entities such as Shire and Sulzer.